What is Dawn?
Dawn operates at the intersection of behavioral health and medical technology, focusing on the development of a scalable standard of care for insomnia treatment. By providing patients with tools to take charge of their sleep health, the company aims to deliver life-changing results while simultaneously addressing the rising costs associated with sleep-related healthcare expenditures. Dawn's platform is designed to integrate seamlessly into existing care pathways, positioning the firm as a critical player in the shift toward digital-first therapeutic solutions.
How much funding has Dawn raised?
Dawn has raised a total of $1.8M across 1 funding round:
Other Financing Round
$1.8M
Other Financing Round (2022): $1.8M with participation from Bragiel Brothers, OnDeck’s Runway Fund, and Kindred Ventures
Key Investors in Dawn
Bragiel Brothers
Bragiel Brothers is a venture firm that provides strategic backing to early-stage companies, often leveraging a diverse portfolio approach to support innovative founders.
Kindred Ventures
Kindred Ventures is a multi-stage investment firm known for backing transformative technology companies, with a deep focus on supporting founders through operational expertise and extensive industry networks.
OnDeck’s Runway Fund
OnDeck’s Runway Fund provides essential capital and community support to high-potential startups, focusing on accelerating growth during critical development phases.
What's next for Dawn?
Looking ahead, Dawn is poised to leverage its recent capital to scale its operations and refine its clinical efficacy models. The company's strategic roadmap likely involves expanding its provider network and enhancing its digital therapeutic platform to meet the needs of a broader patient demographic. As the firm transitions from its current growth phase toward broader market adoption, the focus will remain on demonstrating long-term clinical outcomes and cost-efficiency for health systems. This trajectory suggests a commitment to establishing a sustainable, high-impact model that could redefine how insomnia is managed at scale.
See full Dawn company page
